Julie Jenkins
Family · Montgomery, ALNPI 1194178772
Payments from drug & device makers
Across 489 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Lilly USA, LLC$1K
- Dexcom, Inc.$922
- Novo Nordisk$844
- Bayer$429
- AstraZeneca$409
- plus $4K from 29 others
What the payments were for
- Travel & lodging$8459%
- Food & beverage$8,76191%
- Education$120%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $1,671 |
| Lilly USA, LLC | 86 | $1,466 |
| Dexcom, Inc. | 86 | $922 |
| Novo Nordisk | 42 | $844 |
| Bayer | 37 | $429 |
| AstraZeneca(2 entities) | 23 | $409 |
| Sanofi-aventis U.S. LLC | 20 | $394 |
| Boehringer Ingelheim | 23 | $374 |
| Xeris Pharmaceuticals, Inc. | 17 | $338 |
| Antares Pharma, Inc. | 11 | $337 |
| Corcept Therapeutics | 17 | $302 |
| Amarin Pharma, Inc. | 13 | $257 |
| Amgen | 13 | $232 |
| Abbott | 13 | $229 |
| Mannkind Corporation | 8 | $183 |
| Radius Health, Inc. | 7 | $167 |
| Tandem Diabetes Care, Inc. | 7 | $164 |
| AbbVie | 8 | $151 |
| Insulet Corporation | 7 | $141 |
| BETA Bionics, Inc. | 5 | $131 |
| IBSA Pharma Inc. | 6 | $122 |
| Novartis | 6 | $111 |
| Recordati_rare_diseases_inc. | 3 | $53 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Amryt Pharma Holdings Ltd | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| RGH Enterprises LLC | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Vivus LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$954
- NOCDURNA$131
- XYOSTED$131
How this compares
$9,676 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 882 | $1,217,646 |
| OzempicSemaglutide | 488 | $699,958 |
| JardianceEmpagliflozin | 315 | $321,947 |
| FarxigaDapagliflozin Propanediol | 250 | $227,134 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 141 | $147,067 |
| TrulicityDulaglutide | 99 | $139,308 |
| RybelsusSemaglutide | 82 | $111,224 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 91 | $102,340 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 55 | $100,792 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $96,224 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $74,399 |
| Xigduo XrDapaglifloz Propaned/Metformin | 63 | $72,524 |
| KerendiaFinerenone | 67 | $70,449 |
| Repatha SureclickEvolocumab | 77 | $59,718 |
| VascepaIcosapent Ethyl | 104 | $58,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $1,466 | $1,385,2271,053 claims |
| Novo NordiskOzempic, Rybelsus | $844 | $811,182570 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $374 | $469,014456 claims |
| AstraZenecaFarxiga | $409 | $227,134250 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $394 | $102,34091 claims |
| BayerKerendia | $429 | $70,44967 claims |
| IBSA Pharma Inc.Tirosint | $122 | $15,16357 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $11 | $9,50620 claims |
| AbbVieSynthroid | $151 | $7,06377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Montgomery
- Leigh LunaMontgomery$69K
- Brandy YoungMontgomery$27K
- Angela RaybornMontgomery$22K
- Ashley MorrowMontgomery$21K
- Jackie ShumateMontgomery$19K
- Katrina Jones HarrisMontgomery$18K
- Brittney BarberMontgomery$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.